Zacks Research Comments on Novavax FY2027 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Analysts at Zacks Research issued their FY2027 earnings per share estimates for Novavax in a research report issued on Thursday, March 20th. Zacks Research analyst S. Ganoria expects that the biopharmaceutical company will post earnings of $0.54 per share for the year. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Several other brokerages have also recently commented on NVAX. HC Wainwright reiterated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. BTIG Research started coverage on Novavax in a research note on Friday, February 28th. They set a “buy” rating and a $19.00 price target for the company. Finally, TD Cowen upgraded Novavax to a “hold” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Novavax presently has an average rating of “Hold” and a consensus price target of $18.00.

Novavax Stock Performance

Shares of NASDAQ:NVAX opened at $7.56 on Monday. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -3.35, a P/E/G ratio of 2.85 and a beta of 2.92. The firm has a fifty day moving average price of $8.21 and a 200 day moving average price of $9.44. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to analysts’ expectations of $85.48 million. During the same period in the prior year, the firm posted ($1.44) earnings per share.

Insiders Place Their Bets

In other news, Director James F. Young sold 5,400 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the sale, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.00% of the stock is owned by insiders.

Institutional Trading of Novavax

A number of large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in Novavax during the 4th quarter valued at $27,000. Spire Wealth Management purchased a new position in shares of Novavax during the fourth quarter valued at $29,000. New Age Alpha Advisors LLC bought a new stake in shares of Novavax in the fourth quarter valued at about $35,000. KBC Group NV lifted its stake in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 3,917 shares during the period. Finally, TigerOak Management L.L.C. bought a new position in Novavax during the 4th quarter worth about $86,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.